Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$23.71 USD

23.71
704,441

+0.18 (0.77%)

Updated Apr 26, 2024 02:21 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

by Zacks Equity Research

Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

EXEL vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

EXEL or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?

by Zacks Equity Research

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

by Zacks Equity Research

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

by Zacks Equity Research

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Consider for Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

Exelixis (EXEL) Loses -10.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Exelixis (EXEL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -10% in 4 Weeks, Here's Why You Should You Buy the Dip in Exelixis (EXEL)

by Zacks Equity Research

Exelixis (EXEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Abhinab Dasgupta headshot

3 Medical Stocks to Buy as the Sector Continues to Grow

by Abhinab Dasgupta

HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.

Shaun Pruitt headshot

3 Attractive Medical Stocks to Buy After Earnings

by Shaun Pruitt

Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.

EXEL or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Exelixis (EXEL) Loses -11.72% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Exelixis (EXEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.

Exelixis (EXEL) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Exelixis (EXEL) Tops Q4 Earnings Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 6.45% and 0.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More

by Zacks Equity Research

Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.

Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Exelixis (EXEL) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.